en · de · es
aod-9604-notes.peptides4962.com › Data › Identity And Molecular Context — Research Overview

Identity And Molecular Context — Research Overview

By Editorial Desk · published 2026-06-28 · last reviewed 2026-08-01 · Data

If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity and Molecular Context

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from a fragment of human growth hormone
Sequence basishGH residues 176-191Commonly described as a 16-amino-acid fragment
AppearanceWhite to off-white powderTypical for lyophilized research peptides
SolubilitySoluble in water or aqueous bufferExact solubility depends on pH and purity
Common synonymsAOD9604; hGH 176-191Spelling and punctuation vary across sources

Research and Regulatory Context

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Related pages on this site

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Reference notes

1D-chiro-Inositol or D-chiro-inositol (often abbreviated DCI) is a chemical substance with formula C6H12O6, one of the nine isomers of cyclohexane-1,2,3,4,5,6-hexol (which may be collectively called "inositol"). The molecule has a ring of six carbon atoms, each bound to one hydrogen atom and one hydroxyl (OH) group. The hydroxyls on atoms 1, 2, and 4, in counterclockwise order, lie above the plane of the ring. The molecule being distinct from its mirror image, the compound is chiral, hence its name. Its enantiomer (mirror compound) is 1L-chiro-inositol. Compared to its more common isomer myo-inositol, DCI seems to have relatively minor roles in biochemistry and medicine, mostly connected to the biochemistry of insulin and other hormones.

=== Origins === Before the creation of the Territorial force, there were three "auxiliary forces"—the Militia, the Yeomanry, and the Volunteers. All militiamen over 19 could join the Militia Reserve, accepting the liability to serve overseas with the Regular Army in case of war if called on to do so. The second element of the auxiliary forces was the Yeomanry, 38 regiments of volunteer cavalry, which had historically been used as a form of internal security police. The third arm was the Volunteers, There were 213 rifle corps and 66 corps of artillery, though the latter were mostly coastal artillery or static "position batteries" and they did not constitute an organised field force. There were some engineer and medical units, but no service corps. The Yeomen of the 18th century were cavalry-based units, which were often used to suppress riots (see the Peterloo Massacre). Several units that are now part of the Army Reserve bear the title "militia".

=== Postpartum === If the baby and mother survived the term of the pregnancy, childbirth was then the next step. The tools provided for birth were: towels to catch the blood, a container for the placenta, a pregnancy sash to support the belly, and an infant swaddling wrap. With these tools, the baby was born, cleaned, and swaddled; however, the mother was then immediately the focus of the doctor to replenish her qi. In his writings, Cheng Maoxian places a large amount of emphasis on the Four Diagnostic methods to deal with postpartum issues and instructs all physicians to "not neglect any [of the four methods]". The process of birthing was thought to deplete a woman's blood level and qi so the most common treatments for postpartum were food (commonly garlic and ginseng), medicine, and rest. This process was followed up by a month check-in with the physician, a practice known as zuo yuezi.

which is the expression for the strain energy density of a Neo-Hookean solid. Several compressible versions of the Gent model have been designed. One such model has the form (the below strain energy function yields a non zero hydrostatic stress at no deformation, refer for compressible Gent models).

Sources: en.wikipedia.org

Notes from published material

== Informatics == A major challenge for lipidomics, in particular for MS-based approaches, lies in the computational and bioinformatic demands of handling the large amount of data that arise at various stages along the chain of information acquisition and processing. Chromatographic and MS data collection requires substantial efforts in spectral alignment and statistical evaluation of fluctuations in signal intensities. Such variations have a multitude of origins, including biological variations, sample handling and analytical accuracy. As a consequence several replicates are normally required for reliable determination of lipid levels in complex mixtures. Within the last few years, a number of software packages have been developed by various companies and research groups to analyze data generated by MS profiling of metabolites, including lipids. The data processing for differential profiling usually proceed through several stages, including input file manipulation, spectral filtering, peak detection, chromatographic alignment, normalization, visualization, and data export. An example of metabolic profiling software is the freely-available Java-based Mzmine application. Another is Metabolon, Inc's commercial applications for metabolomic analysis using proprietary software. Recently MS-DIAL 4 software was integrated with a comprehensive lipidome atlas with retention time, collision cross-section and tandem mass spectrometry information for 117 lipid subclasses and 8,051 lipids.

== Iraq War (2003) == Kermani opposed the Iraq War. This opposition notwithstanding, Kermani viewed Saddam Hussein's regime as a terrible terrorist regime, the end of which he welcomed. In the arts section of the Süddeutsche Zeitung and in his book Strategie der Eskalation, Kermani wrote in 2005 that not only the U.S. but also Europe had failed in the Iraq War—and that the Old World was on the verge of repeating the same mistakes in the conflict with Iran. Kermani stated that the "American project to reorganize the Middle East" appeared to be far closer to the hearts of most Iranians today "than the Europeans' policy, which tends to present itself as altruistic". In the article, Kermani calls Europe's pretense that reform efforts still exist in Iran an act of self-deception. As evidence, he cites the suppression of the freedom of the press by Iran's rulers, the imprisonment of opposition figures, and the manipulation of parliamentary elections to restore a "conservative" majority. "War is the wrong means, but liberation is not the wrong end goal", Kermani notes.

=== Key market drivers === Consumer empowerment: Growing interest in preventive healthcare and personal health optimization has driven demand for accessible testing options. Technological advances: Innovations in sample collection (including at-home blood collection with minimal blood volume requirements) and point-of-care testing have made DTC testing more convenient and accessible. Chronic disease prevalence: Rising rates of diabetes (affecting 37.3 million Americans according to the CDC), cardiovascular disease, and other chronic conditions have increased demand for regular monitoring. Cost transparency: DTC services often provide upfront pricing, contrasting with the often opaque costs of traditional healthcare-ordered testing.

Sources: en.wikipedia.org

Background from the literature

Bariatric surgery, particularly Roux-en-Y gastric bypass and sleeve gastrectomy, have demonstrated effectiveness in promoting weight loss and improving diabetes outcomes among severely obese individuals. A 2021 Evidence Update for Clinicians found that Roux-en-Y gastric bypass patients experienced slightly better weight loss and diabetes control outcomes than sleeve gastrectomy patients, though with a higher risk for rehospitalization and need for additional surgeries. In one study there was an unexplained increase in deaths from accidents and suicide, but this did not outweigh the benefit in terms of disease prevention. When the two main techniques are compared, gastric bypass procedures are found to lead to 30% more weight loss than banding procedures one year after surgery. For obese individuals with non-alcoholic fatty liver disease (NAFLD), bariatric surgery improves or cures the liver. A preoperative diet such as low-calorie diets or very-low-calorie diet, is usually recommended to reduce liver volume by 16-20%, and preoperative weight loss is the only factor associated with postoperative weight loss. Preoperative weight loss can reduce operative time and hospital stay. although there is insufficient evidence whether preoperative weight loss may be beneficial to reduce long-term morbidity or complications. Weight loss and decreases in liver size may be independent from the amount of calorie restriction. Ileojejunal bypass, in which the digestive tract is rerouted to bypass the small intestine, was an experimental surgery designed as a remedy for morbid obesity.

=== Diagnosis === It is difficult to differentiate the effects of low level metal poisoning from the environment with other kinds of environmental harms, including nonmetal pollution. Generally, increased exposure to heavy metals in the environment increases the risks for several diseases.

== Knowledge of bacteria == Although an estimated 43,000 species of bacteria have been named, most of them have never been studied. In fact, just 10 bacterial species account for half of all publications, whereas nearly 75% of all named bacteria have no academic research devoted to them. The best-studied species, Escherichia coli, has more than 300,000 studies published on it, but many of these papers likely use it only as a cloning vehicle to study other species, without providing any insight into its own biology. 90% of scientific studies on bacteria focus on less than 1% of species, mostly pathogenic bacteria relevant to human health. While E. coli is probably the best-studied bacterium, a quarter of its 4000 genes are poorly studied or remain uncharacterized. Some bacteria with minimal genomes (< 600 genes, e.g. Mycoplasma) usually have a large fraction of their genes functionally characterized, given that most of them are essential and conserved in many other species.

Nor-LSD, or norLSD, also known as N,N-diethyl-6-norlysergamide or as N-desmethyllysergic acid diethylamide (N-desmethyl-LSD), is a serotonin receptor modulator and putative psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the methyl group at the 6 position of the ergoline ring system has been removed.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

What is the exact length of AOD-9604?

It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.

Does AOD-9604 occur naturally?

It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Network